<?xml version='1.0' encoding='utf-8'?>
<document id="17332142"><sentence text="Evaluation of 3-O-methylfluorescein as a selective fluorometric substrate for CYP2C19 in human liver microsomes."><entity charOffset="14-35" id="DDI-PubMed.17332142.s1.e0" text="3-O-methylfluorescein" /></sentence><sentence text="Cytochrome P450 (P450) fluorometric high-throughput inhibition assays have been widely used for drug-drug interaction screening particularly at the preclinical drug discovery stages" /><sentence text=" Many fluorometric substrates have been investigated for their selectivity, but most are found to be catalyzed by multiple P450 isozymes, limiting their utility" /><sentence text=" In this study, 3-O-methylfluorescein (OMF) was examined as a selective fluorescence substrate for CYP2C19 in human liver microsomes (HLMs)"><entity charOffset="16-37" id="DDI-PubMed.17332142.s4.e0" text="3-O-methylfluorescein" /><entity charOffset="39-42" id="DDI-PubMed.17332142.s4.e1" text="OMF" /><pair ddi="false" e1="DDI-PubMed.17332142.s4.e0" e2="DDI-PubMed.17332142.s4.e0" /><pair ddi="false" e1="DDI-PubMed.17332142.s4.e0" e2="DDI-PubMed.17332142.s4.e1" /></sentence><sentence text=" The kinetic studies of OMF O-demethylation in HLMs using a liquid chromatography/mass spectrometry method exhibited two-enzyme kinetics with apparent K(m) and V(max) values of 1"><entity charOffset="24-26" id="DDI-PubMed.17332142.s5.e0" text="OMF" /></sentence><sentence text="14 +/- 0" /><sentence text="90 microM and 11" /><sentence text="3 +/- 4" /><sentence text="6 pmol/mg/min, respectively, for the high affinity component(s) and 57" /><sentence text="0 +/- 6" /><sentence text="4 microM and 258 +/- 6 pmol/mg/min, respectively, for the low affinity component(s)" /><sentence text=" Studies utilizing cDNA-expressed individual P450 isoforms and P450-selective chemical inhibitors showed that OMF O-demethylation to fluorescein was selective for CYP2C19 at substrate concentrations &lt; or =1 microM"><entity charOffset="110-112" id="DDI-PubMed.17332142.s12.e0" text="OMF" /></sentence><sentence text=" At substrate concentrations &gt; or =10 microM, other P450 isozymes were found to catalyze OMF O-demethylation"><entity charOffset="89-91" id="DDI-PubMed.17332142.s13.e0" text="OMF" /></sentence><sentence text=" In HLMs, analysis of the two-enzyme kinetics in the presence of P450 isozyme-selective chemical inhibitors (ticlopidine for CYP2C19, sulfaphenazole for CYP2C9, and furafylline for CYP1A2) indicated that CYP2C19 was the high affinity component and CYP2C9 was the low affinity component"><entity charOffset="109-120" id="DDI-PubMed.17332142.s14.e0" text="ticlopidine" /><entity charOffset="125-132" id="DDI-PubMed.17332142.s14.e1" text="CYP2C19" /><entity charOffset="134-148" id="DDI-PubMed.17332142.s14.e2" text="sulfaphenazole" /><entity charOffset="153-159" id="DDI-PubMed.17332142.s14.e3" text="CYP2C9" /><entity charOffset="165-176" id="DDI-PubMed.17332142.s14.e4" text="furafylline" /><pair ddi="false" e1="DDI-PubMed.17332142.s14.e0" e2="DDI-PubMed.17332142.s14.e0" /><pair ddi="false" e1="DDI-PubMed.17332142.s14.e0" e2="DDI-PubMed.17332142.s14.e1" /><pair ddi="false" e1="DDI-PubMed.17332142.s14.e0" e2="DDI-PubMed.17332142.s14.e2" /><pair ddi="false" e1="DDI-PubMed.17332142.s14.e0" e2="DDI-PubMed.17332142.s14.e3" /><pair ddi="false" e1="DDI-PubMed.17332142.s14.e0" e2="DDI-PubMed.17332142.s14.e4" /><pair ddi="false" e1="DDI-PubMed.17332142.s14.e1" e2="DDI-PubMed.17332142.s14.e1" /><pair ddi="false" e1="DDI-PubMed.17332142.s14.e1" e2="DDI-PubMed.17332142.s14.e2" /><pair ddi="false" e1="DDI-PubMed.17332142.s14.e1" e2="DDI-PubMed.17332142.s14.e3" /><pair ddi="false" e1="DDI-PubMed.17332142.s14.e1" e2="DDI-PubMed.17332142.s14.e4" /><pair ddi="false" e1="DDI-PubMed.17332142.s14.e2" e2="DDI-PubMed.17332142.s14.e2" /><pair ddi="false" e1="DDI-PubMed.17332142.s14.e2" e2="DDI-PubMed.17332142.s14.e3" /><pair ddi="false" e1="DDI-PubMed.17332142.s14.e2" e2="DDI-PubMed.17332142.s14.e4" /><pair ddi="false" e1="DDI-PubMed.17332142.s14.e3" e2="DDI-PubMed.17332142.s14.e3" /><pair ddi="false" e1="DDI-PubMed.17332142.s14.e3" e2="DDI-PubMed.17332142.s14.e4" /></sentence><sentence text=" Based on these findings, a fluorometric assay was developed using 1 microM OMF and 2 microM sulfaphenazole for probing CYP2C19-mediated inhibition in HLMs"><entity charOffset="93-107" id="DDI-PubMed.17332142.s15.e0" text="sulfaphenazole" /><entity charOffset="76-89" id="DDI-PubMed.17332142.s15.e1" text="OMF" /><pair ddi="false" e1="DDI-PubMed.17332142.s15.e1" e2="DDI-PubMed.17332142.s15.e1" /><pair ddi="false" e1="DDI-PubMed.17332142.s15.e1" e2="DDI-PubMed.17332142.s15.e0" /></sentence><sentence text=" The IC(50) data of 13 substrates obtained from the fluorometric assay developed in this study correlated well with that reported in the literature using nonfluorescence assays" /><sentence text="" /></document>